Close

Cartesian Therapeutics (RNAC) Doses First Patient in Phase 2 Trial of Descartes-08 Jul 2, 2024 06:32AM
Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus Jul 2, 2024 06:31AM
Cartesian Therapeutics (RNAC) Reports Positive Topline Results from Phase 2b Trial of Descartes-08 Jul 2, 2024 06:30AM
Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis Jul 2, 2024 06:30AM
Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ May 13, 2024 04:30PM


May 8, 2024 07:00AM Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Apr 22, 2024 04:30PM Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting
Apr 4, 2024 07:30AM Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Mar 7, 2024 07:00AM Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Mar 6, 2024 07:00AM Cartesian Therapeutics to Participate in Upcoming Investor Conferences
Mar 5, 2024 07:05AM Cartesian Therapeutics Announces New Employment Inducement Grant
Mar 5, 2024 07:00AM Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland